Primary cancers can be prevented by immunizations. We suggest immunizing healthy people, especially the ones with genetic predisposition to cancer, with a standard oncoantigen. In patients suffering from cancer, immunotherapy can be effective only if it is administered during complete remission. Immune competent cells, like T-lymphocytes and bone marrow, are the most important components for cancer prevention and treatment. Because of the dramatic increase in the incidence of cancer, it is important to offer all adults with absolutely healthy immune system an opportunity to donate their own T-lymphocytes and bone marrow cells and preserve them at -196。C. These cells can later be used by the same people in auto-system if they develop cancer. Patients who had their cancerous tumors surgically removed can also have their own T-lymphocytes and bone marrow cells collected during remission and then used in auto-system in case of cancer reoccurrence. It is also possible to impact on cancer development during the process of cancerogenesis by administering large amounts of normal DNA and possibly different types of RNA (displacement) together with nucleases (directly into the tumor or blood). In addition, blockers of cytokines that suppress immune system should be administered as well. It is intriguing to think that injection of large amounts of normal DNA and possibly different types of RNA together with nucleases to patients with chronic and hereditary diseases (diabetes Type II, schizophrenia, and other similar diseases) can lead to therapeutic effect.
Cite this paper
Skurkovich, S. and Skurkovich, B. (2014) Prevention of Cancer and Cancer Re-Occurrences by Immunization, by Using Immune Competent Cells, and by Affecting Molecular Mechanisms of Cancerogenesis. Journal of Immune Based Therapies, Vaccines and Antimicrobials
, 33-36. doi: 10.4236/jibtva.2014.33005
 Skurkovich, S.V., Kislyak, N.S., Machonova, L.A. and Begunenko, S.A. (1969) Active Immunization of Children Suffering from Acute Leukaemia in Acute Phase with “Live” Allogeneic Leukaemic Cells. Nature, 223, 509-511.
 Skurkovich, S.V., Klinova, E.G., Eremkina, E.I. and Levina, N.V. (1974) Immunosuppressive Effect of an Anti-Interferon Serum. Nature, 247, 551-552. http://dx.doi.org/10.1038/247551a0
 Skurkovich, S., Bulycheva, T., Mayakova, S. and Mahonova, L. (2008) Successful Immunotherapy of Acute Lymphoblastic Leukemia (ALL) in Children and Perspectives for Prevention of Solid Cancer. BIT Life Sciences’ 1st Annual World Cancer Congress, 12-15 June 2008, Shanghai, 480.
 Bulychova, T., Mayakova, S. and Skurkovich, S. (2013) Disease-Free Remission Exceeding 37 Years in Patients Treated as Children for Acute Leukemia (AL) with Immunotherapy Using Viable (Cryopreserved) Allogeneic Leukemic Cells. Journal of Cancer Research Updates, 2, 254-264.
 Skurkovich, S.V. (1971) Immunotherapy of Leukemia. Problemy gematologii i perelivaniia krovi, 16, 3-10.
 Davis, I.D., Chen, W., Jackson, H., et al. (2004) Recombinant NY-ESO-1 Protein with ISCOMATRIX Adjuvant Induces Broad Integrated Antibody and CD4+ and CD8+ T Cell Responses in Humans. Proceedings of the National Academy of Sciences of the USA, 101, 10697-10702. http://dx.doi.org/10.1073/pnas.0403572101
 Rosenberg, S.A. (1987) US Patent 4690915.
 Lindahl, P., Leary, P. and Gresser, I. (1973) Enhancement by Interferon of the Expression of Surface Antigens on Murine Leukemia l 1210 Cells. Proceedings of the National Academy of Sciences of the USA, 70, 2785-2788.
 Skurkovich, S.V., Olshanskaya, N.V. and Eremkina, E.I. (1976) Intensification of Cellular Immune Response By immunization of Mice with the Cells Preincubated Ininterferon. Bulletin of Experimental Biology and Medicine, 82, 1230-1232.
 Linn, S. and Arber, W. (1968) Host Specificity of DNA Produced by Escherichia coli, X. In Vitro Restriction of Phage fd Replicative form. Proceedings of the National Academy of Sciences of the USA, 59, 1300-1306.
 Linn, S., Lloyd, R. and Roberts, R. (1993) Nucleases. 2nd Edition.
 Sladek, R., et al. (2007) A Genome-Wide Association Study Identifies Novel Risk Loci for Type 2 Diabetes. Nature, 445, 881-885. http://dx.doi.org/10.1038/nature05616
 O’Donovan, M.C., Williams, N.M. and Owen, M.J. (2003) Recent Advances in the Genetics of Schizophrenia. Human Molecular Genetics, 12, R125-R133. http://dx.doi.org/10.1093/hmg/ddg302